{
    "clinical_study": {
        "@rank": "119174", 
        "arm_group": [
            {
                "arm_group_label": "MK-1602 1 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "MK-1602 10 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "MK-1602 25 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "MK-1602 50 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "MK-1602 100 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to characterize the pharmacokinetics of MK-1602 in the\n      treatment of acute migraine, including the influence of demographic and other variables on\n      MK-1602 pharmacokinetics, and to evaluate the relationship between MK-1602 concentrations\n      and efficacy of the drug."
        }, 
        "brief_title": "A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Migraine", 
        "condition_browse": {
            "mesh_term": "Migraine Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  > 1 year history of migraine with or without aura as defined by International\n             Headache Society (IHS) criteria 1.1 and/or 1.2\n\n          -  Migraines typically last between 4 to 72 hours, if untreated\n\n          -  \u2265 2 and \u2264 8 moderate or severe migraine attacks per month in each of\n\n        the two months prior to screening\n\n          -  Male, female who is not of reproductive potential, or female of\n\n        reproductive potential with a screening serum \u03b2-human chorionic gonadotropin (\u03b2-hCG) level\n        consistent with a not-pregnant state, and who agrees to use acceptable contraception\n\n        Exclusion Criteria:\n\n          -  Pregnant or breast-feeding, or is a female expecting to conceive within the projected\n             duration of study participation\n\n          -  Participant has difficulty distinguishing his/her migraine attacks from tension-type\n             headaches\n\n          -  History of predominantly mild migraine attacks or migraines that usually\n\n        resolve spontaneously in less than two hours\n\n          -  More than 15 headache-days per month or has taken medication for acute headache on\n             more than 10 days per month in any of the three months prior to screening\n\n          -  Basilar-type or hemiplegic migraine headache\n\n          -  > 50 years old at age of migraine onset\n\n          -  Taking migraine prophylactic medication where the prescribed daily dose\n\n        has changed during the 3 months prior to screening and during the study\n\n          -  Taking a proton pump inhibitor (PPI) or a histamine receptor 2 (H2) blocker on a\n             daily or near daily basis (> 3 days per week)\n\n          -  Taking the following medications from 1 month prior to screening through study\n             period: potent cytochrome P450 (CYP) 3A4 inhibitors (e.g., cyclosporine,\n             itraconazole, ketoconazole, fluconazole, erythromycin, clarithromycin, nefazodone,\n             telithromycin, cimetidine, quinine, diltiazem, verapamil, modafinil and human\n             immunodeficiency virus [HIV] protease inhibitors), moderate or marked CYP3A4 inducers\n             (e.g., rifampicin, rifabutin, barbiturates [e.g., phenobarbital and primidone],\n             systemic glucocorticoids, nevirapine, efavirenz, pioglitazone, carbamazepine,\n             phenytoin, and St. Johns wort), or drugs with narrow therapeutic margins and\n             potential for drug interactions in the CYP2C family (e.g., warfarin)\n\n          -  Participant is unable to refrain from consumption of grapefruit or grapefruit juice\n             during study\n\n          -  History of hypersensitivity to, or has experienced a serious adverse event\n\n        in response to 3 or more classes of drugs (prescription and over-the-counter)\n\n          -  Clinical or laboratory evidence of uncontrolled diabetes, HIV disease, or significant\n             pulmonary, renal, hepatic, endocrine, or other systemic disease\n\n          -  Other confounding pain syndromes, psychiatric conditions such as uncontrolled major\n             depression, dementia or significant neurological disorders other than migraine.\n             Patients who are currently being treated with non-prohibited medication for\n             depression and symptoms are well controlled are eligible to participate\n\n          -  Participant is at imminent risk of self-harm\n\n          -  History of malignancy \u2264 5 years prior to study, except for adequately treated basal\n             cell or squamous cell skin cancer, or in situ cervical cancer\n\n          -  History of gastric or small intestinal surgery (including gastric bypass\n\n        surgery or banding), or presence of a disease that causes malabsorption\n\n          -  History or current evidence of any condition, therapy, lab abnormality or\n\n        other circumstance that might confound the results of the study, or interfere with\n        subject's participation for the full duration of the study\n\n          -  Participant has recent history (within the last year) of drug or alcohol abuse or\n             dependence or is a user of recreational or illicit drugs\n\n          -  Participant is legally or mentally incapacitated\n\n          -  Donation of blood products or phlebotomy of > 300 ml within 8\n\n        weeks of study, or intent to donate blood products or receive\n\n        blood products within 30 days of screening and throughout study\n\n          -  Intent to donate eggs or sperm within the projected duration of the\n\n        study\n\n          -  Current participation in or participation within 30 days of screening\n\n        in a study with an investigational compound or device, with the exception of MK-1602\n        Protocol 006\n\n          -  Previous exposure to MK-0974 and/or MK-3207\n\n          -  Use within the past 2 months of an opioid- or barbiturate-containing\n\n        analgesic for migraine relief\n\n          -  Inpatient or emergency department treatment of an acute migraine\n\n        attack within the past 2 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "195", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01657370", 
            "org_study_id": "1602-007"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "MK-1602 1 mg", 
                    "MK-1602 10 mg", 
                    "MK-1602 25 mg", 
                    "MK-1602 50 mg", 
                    "MK-1602 100 mg"
                ], 
                "description": "Three administrations of the same dose of MK-1602 on separate days. All 3 doses are either 1, 10, 25, 50 or 100 mg of MK-1602. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).\nDosage form is film coated tablet for oral administration.", 
                "intervention_name": "MK-1602", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Three administrations of placebo for MK-1602 on separate days. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).\nDosage form is film coated tablet for oral administration.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MK-1602 1 mg", 
                    "MK-1602 10 mg", 
                    "MK-1602 25 mg", 
                    "MK-1602 50 mg", 
                    "MK-1602 100 mg", 
                    "Placebo"
                ], 
                "description": "If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,\nparticipants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs]), anti-emetics, triptans, opiates or other medication not explicitly excluded.", 
                "intervention_name": "Rescue medication", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 21, 2014", 
        "number_of_arms": "6", 
        "official_title": "A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Dry Blood Spot MK-1602 concentration at 2 hours post dose on migraine treatment day", 
                "safety_issue": "No", 
                "time_frame": "2 hours post dose 1"
            }, 
            {
                "measure": "Pain freedom (PF) at 2 hours post dose on migraine treatment day", 
                "safety_issue": "No", 
                "time_frame": "2 hours post dose 1"
            }, 
            {
                "measure": "Pain relief (PR) at 2 hours post dose on migraine treatment day", 
                "safety_issue": "No", 
                "time_frame": "2 hours post dose 1"
            }
        ], 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01657370"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Dry Blood Spot MK-1602 concentrations on migraine treatment day", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 hours post dose 1"
            }, 
            {
                "measure": "Dry Blood Spot MK-1602 concentration at 3.5 hours post dose on Visit 2", 
                "safety_issue": "No", 
                "time_frame": "3.5 hours post dose 3"
            }, 
            {
                "measure": "Plasma MK-1602 concentrations at Visit 2", 
                "safety_issue": "No", 
                "time_frame": "Up to 3.5 hours post dose 3"
            }, 
            {
                "measure": "Absence of phonophobia at 2 hours post dose on migraine treatment day", 
                "safety_issue": "No", 
                "time_frame": "2 hours post dose 1"
            }, 
            {
                "measure": "Absence of photophobia at 2 hours post dose on migraine treatment day", 
                "safety_issue": "No", 
                "time_frame": "2 hours post dose 1"
            }, 
            {
                "measure": "Absence of nausea at 2 hours post dose on migraine treatment day", 
                "safety_issue": "No", 
                "time_frame": "2 hours post dose 1"
            }, 
            {
                "description": "SPF is defined as PF at 2 hours post dose, with no administration of any rescue medication and with no occurrence of a mild/moderate/severe\nheadache during the 2-24 hour period after dosing with study medication.", 
                "measure": "Sustained pain freedom (SPF) from 2-24 hours post dose on migraine treatment day", 
                "safety_issue": "No", 
                "time_frame": "2-24 hours post dose 1"
            }, 
            {
                "description": "SPR is defined as PR at 2 hours post dose, with no administration of any rescue medication and with no occurrence of a moderate/severe headache during the 2-24 hour period after dosing with study medication.", 
                "measure": "Sustained pain relief (SPR) from 2-24 hours post dose on migraine treatment day", 
                "safety_issue": "No", 
                "time_frame": "2-24 hours post dose 1"
            }, 
            {
                "description": "TMF at 2 hours post dose is defined as PF with no photophobia, phonophobia, nausea, or vomiting at 2 hours post dose.", 
                "measure": "Total migraine freedom (TMF) at 2 hours post dose on migraine treatment day", 
                "safety_issue": "No", 
                "time_frame": "2 hours post dose 1"
            }, 
            {
                "description": "TMF from 2-24 hours post dose is defined as SPF with no photophobia, phonophobia, nausea, or vomiting during the 2-24 hour period after dosing with study medication.", 
                "measure": "TMF from 2-24 hours post dose on migraine treatment day", 
                "safety_issue": "No", 
                "time_frame": "2-24 hours post dose 1"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}